Instrument Inactif

Communiqués Genovis AB (publ.) Nasdaq Stockholm

Actions

GenovisQ1 2024 - Financials in line with expectations, strong outlook	16/05	AQ
Interim Report January - March 2024	15/05	AQ
Genovis Annual Report 2023 published	24/04	AQ
NOTICE CONVENING THE 2024 ANNUAL GENERAL MEETING	09/04	AQ
Carthesian Therapeutics terminates Genovis Licence Agreement	14/03	AQ
Genovis Q4 2023 - Soft ending but promising start	19/02	AQ
Year-end report January-December 2023	15/02	AQ
Genovis to receive USD 1 million in milestone compensation related to the development of the Xork™ enzyme	13/02	AQ
Genovis AB changes Certified Adviser to Carnegie Investment Bank AB (publ)	30/11	AQ
Genovis Q3 2023 - Solid growth and profitability, Xork timeline remains on track	16/11	AQ
Genovis Q2 2023 - Strong growth and expanding EBIT margin	25/08/23	AQ
Half-Yearly Report January-June 2023	24/08/23	AQ
Genovis launch Innovative IgM-Specific Protease with Wide-Ranging Applications in Life Science Markets	02/06/23	AQ
Genovis Q1 2023 - Strongest report to date	17/05/23	AQ
Communiqué from Genovis AB (publ) Annual General Meeting May 16, 2023	16/05/23	AQ
Interim Report January-March 2023	16/05/23	AQ
ArcticZymes Technologies and Genovis enter into a collaboration agreement to accelerate growth in China.	03/05/23	AQ
Genovis and ArcticZymes Technologies enter into a collaboration agreement to accelerate growth in China	03/05/23	AQ
Genovis acquires IP Rights to novel enzymes for applications within genomics	25/04/23	AQ
Genovis Annual Report 2022 published	25/04/23	AQ

Aucun résultat pour cette recherche